Pliant Therapeutics. has been granted a patent for integrin inhibitors, including crystalline forms of their phosphate salts. The patent details methods for preparing these forms and their potential use in treating fibrotic diseases, supported by specific X-ray powder diffraction data. GlobalData’s report on Pliant Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Pliant Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Pliant Therapeutics's grant share as of June 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Integrin inhibitors for treating fibrotic diseases
The granted patent US12018025B2 describes various crystalline forms of a specific compound, (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, in different salt forms, including phosphate, fumarate, and 1,5-naphthalenedisulfonate. Each crystalline form is characterized by distinct X-ray powder diffraction (XRPD) patterns, which include specific peak angles (2-theta) that serve as identifiers for the crystalline structures. Additionally, the patent outlines thermal properties determined by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA), indicating endothermic peaks and weight loss percentages at various temperature ranges. The patent also specifies the water content of these crystalline forms, with some being hydrates and others being anhydrous.
Furthermore, the patent details methods for preparing these crystalline forms, which involve mixing the compound with various acids in specific solvents, often under controlled temperature conditions. The applications of these crystalline forms are highlighted, particularly in the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The methods of administration and the potential for modulating integrin activity in individuals are also discussed, emphasizing the therapeutic significance of these crystalline forms in clinical settings. The patent includes claims for pharmaceutical compositions containing these crystalline forms, as well as kits designed for treating specific fibrotic conditions.
To know more about GlobalData’s detailed insights on Pliant Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
